Join the Oncology Voice Network. Join for Free
"The Road Less Traveled: Leveraging an Unconventional Career Path"
Medical Science Liaison Marc Bernarducci MSL career advice unconventional career path transitioning to industry

"The Road Less Traveled: Leveraging an Unconventional Career Path"


Share This Article


Summary

In this episode, Tom Caravela is joined by Marc Bernarducci to explore the evolving role of Medical Science Liaisons. Marc shares insights from his educational journey and transition into the industry, highlighting the significance of networking and tenacity. He emphasizes patience and coachability during job searches and new roles, and discusses the complexities of the MSL position, including learning from mistakes. The conversation shifts to adapting to digital platforms and preparing for the post-COVID landscape, stressing the importance of adaptability. Marc concludes with valuable advice for aspiring MSLs, followed by closing remarks and holiday wishes.

Marc Bernarducci, Sr Medical Science Liaison shares ideas on leveraging an unconventional career path to find success.

In this episode we discuss:

  • Marc’s education and where his career began
  • What made him want to transition to industry and how did he go about it
  • How he landed in medical affairs and why he wanted to be an MSL
  • His perspective on “unconventional” career path
  • His advice for others who are looking to break into their first MSL role
  • His other advice to those that are looking to build a career in Medical Affairs

Click for Source
Medical Science Liaison, Marc Bernarducci, MSL career advice, unconventional career path, transitioning to industry

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN